Arcus Biosciences (RCUS) Gets a Hold from Bank of America Securities
In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
There's been a notable change in appetite for Arcus Biosciences, Inc. ( NYSE:RCUS ) shares in the week since its ...
Hosted on MSN1d
HC Wainwright & Co. Upgrades Arcus Biosciences (RCUS)
Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...
Arcus Biosciences upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 ...
2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...
FierceBiotech10d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Business Wire10d
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...
Arcus Biosciences Shares Hit 52-Week Low After $150M Stock Offering
Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Target Price from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” ...